Catalog 01 Resources 02 How to order 03 CalculatorBlog Cart 03 Home 04
GH & Secretagogues

CJC-1295 No DAC + Ipamorelin Australia — Batch-Verified

CJC-1295 without DAC 5mg + IPA 5mg research peptide vial — TXLABS, ≥98% HPLC

From $79 AUD · ≥98% HPLC purity · third-party COA · ships Australia-wide

What is CJC-1295 without DAC 5mg + IPA 5mg?

CJC-1295 without DAC + Ipamorelin (IPA) is a research blend pairing a short-acting GHRH analogue with a selective ghrelin receptor agonist. The Mod GRF 1-29 component acts on the GHRH receptor while Ipamorelin activates the ghrelin/GHS-R pathway, and the blend is studied for complementary growth hormone release.

Specifications

Certificate of Analysis◆ 3rd-party tested
Janoshik Certificate of Analysis for CJC-1295 without DAC 5mg + IPA 5mg, batch CS-c/i55-0228View full report ↗
AnalyteCJC-1295 (mod GRF 1-29) + Ipamorelin
Assay6.61 mg + 6.04 mg / label 5 mg + 5 mg
LabJanoshik
BatchCS-c/i55-0228
Tested16 MAR 2026

Report ID and verification key are redacted on our copy of this certificate. Request the unredacted report, or see the full CoA library.

This sample is quantified by assay mass — the laboratory did not report a purity percentage for it. Where a vial holds two peptides, each is measured separately and a single combined purity figure is not meaningful.

What the research covers

This vial contains two distinct research peptides co-lyophilised in a single cake: CJC-1295 without DAC and ipamorelin, nominally 5 mg of each. They are separate molecules acting at separate receptors, and the certificate treats them separately.

CJC-1295 without DAC is more precisely described as modified GRF(1-29), a truncated analogue of growth hormone-releasing hormone. It uses the first 29 residues of GHRH, the shortest fragment retaining full agonist activity, with four amino acid substitutions reported as D-Ala at position 2, Gln at 8, Ala at 15 and Leu at 27. The D-Ala substitution is the functionally important one: it blocks dipeptidyl peptidase-4 cleavage at the N-terminus, which is the principal degradation route for native GHRH. Its molecular weight is in the region of 3.4 kDa, close to that of sermorelin (GHRH 1-29) at 3357.9 Da. The absence of a drug affinity complex, the maleimide group that lets the DAC-modified version bind covalently to serum albumin, is what the without DAC designation denotes, and it is the reason the two versions have very different reported half-lives in the literature.

Ipamorelin is a pentapeptide of 711.9 Da acting at the growth hormone secretagogue receptor GHS-R1a, the ghrelin receptor. Research literature pairs GHRH analogues with GHS-R1a agonists because they represent two independent inputs converging on the same pituitary somatotroph population, and studies of that convergence have examined whether combined receptor engagement produces additive or synergistic secretory responses in cell and animal models.

TXLABS supplies the combination as a laboratory reference material only. It is not an approved therapeutic good in Australia and is not supplied for human or veterinary administration.

Reading the certificate

For blends the single most important CoA feature is per-component assay. A combined purity percentage is not meaningful when a vial contains two different molecules, and any certificate offering one for a blend should be treated with suspicion. What matters is that the laboratory quantified each peptide separately and reported both masses. The two components here differ by roughly 2.7 kDa, so reversed-phase HPLC and mass spectrometry separate them easily and there is no technical excuse for a combined figure. TXLABS publishes the Janoshik Analytical report for this blend in the CoA library: batch CS-c/i55-0228, tested 16 March 2026, reporting 6.61 mg of CJC-1295 (mod GRF 1-29) and 6.04 mg of ipamorelin against a 5 mg plus 5 mg label. The library marks it assay only rather than inventing a purity percentage.

Storage and handling

A co-lyophilised blend is stored on the terms of its least stable component, which here is the 29-residue GHRH analogue rather than the pentapeptide. Hold the lyophilised cake at -20 °C, desiccated and protected from light, and let it reach room temperature before opening so that condensation does not wet the powder. Once reconstituted, both peptides are in the same solution and cannot be separated, so any handling error affects the whole vial: keep solution at 2-8 °C in the dark, add diluent gently down the vial wall, and swirl rather than shake. Aliquot before freezing if extended storage is needed, since freeze-thaw stress acts on the longer peptide first. In Australian conditions the blend is worth treating with slightly more caution than a single short peptide, because degradation of one component changes the effective ratio in the vial without any visible sign. Prompt parcel collection and immediate refrigeration are the practical safeguards against summer transit temperatures above 40 °C.

Working out concentration

For a blend, concentration must be tracked per component. The vial is nominally 5 mg CJC-1295 without DAC plus 5 mg ipamorelin, 10 mg of peptide in total. Reconstituted with 2 mL of bacteriostatic water, that gives 2.5 mg/mL of each peptide and 5 mg/mL of total peptide; with 1 mL it gives 5 mg/mL of each and 10 mg/mL total. Recording only the total figure is the common error, because it silently doubles the apparent concentration of either component. The reconstitution calculator will handle the vial mass and volume. These are concentration examples only, not a protocol.

How it relates to adjacent compounds

This vial is the combination form of two compounds also stocked separately. Ipamorelin is available as a standalone 10 mg vial, and the GHRH-analogue side of the pairing has a full-length structural relative in tesamorelin, which uses the complete 44-residue GHRH sequence with an N-terminal acyl group instead of the 29-residue fragment with internal substitutions. The relationship between modified GRF(1-29) and CJC-1295 with DAC is one of albumin-binding chemistry: the DAC version adds a maleimide group absent here. All of these are structural and receptor-level relationships and imply nothing about relative effect. Buying the blend rather than the two single vials is a question of experimental design and record-keeping, since the molecules themselves are identical either way.

Frequently asked questions

What exactly is in this vial? +
Two separate peptides co-lyophilised in one cake: nominally 5 mg of CJC-1295 without DAC, more accurately called modified GRF(1-29), and 5 mg of ipamorelin. They are chemically distinct molecules acting at different receptors, roughly 3.4 kDa and 711.9 Da respectively, and are quantified separately on the certificate of analysis.
What does without DAC mean? +
DAC stands for drug affinity complex, a maleimide group attached to the peptide that reacts with serum albumin to form a covalent conjugate and greatly extend circulating half-life. The without DAC version omits that group entirely, so the molecule is simply the tetrasubstituted GHRH(1-29) analogue. The two versions have distinct molecular masses and distinct pharmacokinetics in the published literature.
Why is there no single purity percentage on the certificate? +
Because a combined purity number for a two-peptide vial is not a meaningful measurement. The laboratory quantifies each component separately by reversed-phase HPLC, so the informative figures are the two assay masses. TXLABS marks blend reports assay only in <a href="/coa-library">the CoA library</a> rather than publishing a single percentage that would misrepresent what was measured.
What does the published certificate report for this blend? +
The Janoshik Analytical report covers batch CS-c/i55-0228, tested 16 March 2026, and reports 6.61 mg of CJC-1295 (mod GRF 1-29) and 6.04 mg of ipamorelin against a labelled 5 mg plus 5 mg. Both components were quantified independently. As with all certificates, the document describes that specific lot rather than the product line.
Why do blends need more careful storage than single peptides? +
Because the two components degrade at different rates and there is no visible sign when the ratio shifts. The 29-residue GHRH analogue is more vulnerable to freeze-thaw stress and aggregation than the five-residue ipamorelin, so a mishandled vial may still look correct while containing a different proportion than the label states. Store on the terms of the less stable component.
Are these compounds scheduled in Australia? +
Scheduling status is set by the Poisons Standard and revised by the TGA on a regular cycle, so it is date-dependent and should not be assumed from any supplier page. Neither component is registered on the ARTG, and the TGA has published specific guidance on unapproved peptide products naming CJC-1295 among them. Check tga.gov.au for the current position.
Can the two components be separated after reconstitution? +
No. Once diluent is added the peptides are in a single solution and cannot be practically separated outside an analytical laboratory. That is why the per-component assay figures on the certificate matter: they are the only record of how much of each molecule the vial contained before reconstitution, and the reason concentration should be tracked per component rather than as a total.

Related compounds

Browse full catalog Reconstitution calculator